David J. Woodhouse - Mar 3, 2022 Form 4 Insider Report for NGM BIOPHARMACEUTICALS INC (NGM)

Role
Chief Executive Officer, Director
Signature
/s/ Valerie Pierce, Attorney-in-fact
Stock symbol
NGM
Transactions as of
Mar 3, 2022
Transactions value $
$0
Form type
4
Date filed
3/4/2022, 03:06 PM
Previous filing
Dec 30, 2021
Next filing
Jun 9, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NGM Stock Option (Right to Buy) Award $0 +500K $0.00 500K Mar 3, 2022 Common Stock 500K $15.20 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the stock option vest over a four-year period commencing January 1, 2022, with 1/48th of the shares vesting on a monthly basis.